Brian Daniels, MD

Venture Partner

Brian Daniels, M.D. joined 5AM Ventures in 2014 as a Venture Partner. Prior to his joining, Dr. Daniels spent over two decades in clinical drug development including the last ten years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He directed the development of numerous innovative medicines that have contributed to improvements for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolics, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director of Spyryx Biosciences and served on the Scientific Advisory Board of Novira. Dr. Daniels received B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF. Dr. Daniels is based in the San Francisco, CA office.